Mealey's (September 27, 2019, 10:39 AM EDT) -- ALEXANDRIA, Va. — In a Sept. 26 petition, Biogen MA Inc. told the Patent Trial and Appeal Board that it erred in instituting inter partes review (IPR) of a patented multiple sclerosis (MS) treatment method, as well as in joining several petitioners to a pre-existing IPR proceeding (Mylan Pharmaceuticals Inc., et al. v. Biogen MA Inc., No. IPR2018-01403, PTAB)....